Directrices españolas basadas en la evidencia para el tratamiento de la psoriasis moderada a grave con agentes biológicos (Q58764407)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19558918%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

title

[Spanish evidence-based guidelines on the treatment of moderate-to-severe psoriasis with biologic agents] (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19558918%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19558918%20AND%20SRC:MED&resulttype=core&format=json

Vicente García-Patos Briones

1 February 2020

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19558918%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

author name string

J M Carrascosa

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19558918%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

E Daudén

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19558918%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

J L Sánchez-Carazo

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19558918%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

C Ferrándiz

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19558918%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

M Sánchez-Regaña

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19558918%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

M García-Bustinduy

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19558918%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

X Bordas

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19558918%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

J C Moreno

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19558918%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

J M Hernanz

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19558918%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

S Laguarda

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19558918%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

Grupo Español de Psoriasis de la Academia Española de Dermatología y Venereología

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19558918%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

publication date

1 June 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19558918%20AND%20SRC:MED&resulttype=core&format=json

Actas Dermo-Sifiliográficas

1 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19558918%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

volume

100

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19558918%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19558918%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

page(s)

386-413

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19558918%20AND%20SRC:MED&resulttype=core&format=json

Prevalence of psoriasis in Spain (Epiderma Project: phase I)

1 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2809%2971257-8

[Psoriasis, a systemic disease?]

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2809%2971257-8

Psoriasis causes as much disability as other major medical diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2809%2971257-8

Epidemiology of psoriatic arthritis in the population of the United States.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2809%2971257-8

Clinical characteristics of psoriatic arthritis and psoriasis in dermatologists' offices

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2809%2971257-8

The psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2809%2971257-8

Current severe psoriasis and the rule of tens.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2809%2971257-8

National Psoriasis Foundation clinical consensus on disease severity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2809%2971257-8

Biological therapies in the systemic management of psoriasis: International Consensus Conference

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2809%2971257-8

German evidence-based guidelines for the treatment of Psoriasis vulgaris (short version).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2809%2971257-8

European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2809%2971257-8

Members of the National Psoriasis Foundation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2809%2971257-8

British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2809%2971257-8

Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2809%2971257-8

Evidence-based (S3) guidelines for the treatment of psoriasis vulgaris.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2809%2971257-8

Comparative effects of biological therapies on the severity of skin symptoms and health-related quality of life in patients with plaque-type psoriasis: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2809%2971257-8

Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2809%2971257-8

Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2809%2971257-8

Efalizumab in the treatment of psoriasis: mode of action, clinical indications, efficacy, and safety

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2809%2971257-8

A novel targeted T-cell modulator, efalizumab, for plaque psoriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2809%2971257-8

Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2809%2971257-8

Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2809%2971257-8

Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2809%2971257-8

Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2809%2971257-8

CLinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2809%2971257-8

Clinical Experience Acquired with Raptiva (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from extended treatment in an international, Phase III, placebo-controlled trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2809%2971257-8

Long-term continuous efalizumab therapy in patients with moderate to severe chronic plaque psoriasis: updated results from an ongoing trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2809%2971257-8

Efalizumab: results of a 3-year continuous dosing study for the long-term control of psoriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2809%2971257-8

Efalizumab in routine use: a clinical experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2809%2971257-8

The effect of weight on the efficacy of biologic therapy in patients with psoriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2809%2971257-8

Safety and efficacy of subcutaneously administered efalizumab in adults with moderate-to-severe hand and foot psoriasis: an open-label study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2809%2971257-8

Successful treatment of recalcitrant palmoplantar psoriasis with efalizumab

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2809%2971257-8

A review of malignancies observed during efalizumab (Raptiva) clinical trials for plaque psoriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2809%2971257-8

Incidence of infection during efalizumab therapy for psoriasis: analysis of the clinical trial experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2809%2971257-8

National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2809%2971257-8

Strategies to improve treatment with efalizumab

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2809%2971257-8

Effective management of a psoriatic flare with narrowband UVB phototherapy during efalizumab therapy without discontinuing treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2809%2971257-8

Managing moderate-to-severe psoriasis with efalizumab: experience at a single Spanish institute

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2809%2971257-8

Efalizumab retreatment in patients with moderate to severe chronic plaque psoriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2809%2971257-8

Relapse, rebound, and psoriasis adverse events: an advisory group report.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2809%2971257-8

Onset of psoriatic arthritis in patients treated with efalizumab for moderate to severe psoriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2809%2971257-8

Efalizumab for the treatment of psoriatic arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2809%2971257-8

Flare and change of psoriasis morphology during the course of treatment with tumour necrosis factor blockers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2809%2971257-8

Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2809%2971257-8

Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2809%2971257-8

Tumor necrosis factor antagonists in the therapy of psoriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2809%2971257-8

A randomized trial of etanercept as monotherapy for psoriasis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2809%2971257-8

Etanercept as monotherapy in patients with psoriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2809%2971257-8

A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2809%2971257-8

A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2809%2971257-8

Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2809%2971257-8

Efficacy of etanercept in an integrated multistudy database of patients with psoriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2809%2971257-8

Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2809%2971257-8

Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2809%2971257-8

Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2809%2971257-8

Etanercept Treatment for Children and Adolescents with Plaque Psoriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2809%2971257-8

The combination of etanercept and methotrexate increases the effectiveness of treatment in active psoriasis despite inadequate effect of methotrexate therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2809%2971257-8

Etanercept combined with methotrexate for high-need psoriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2809%2971257-8

Etanercept monotherapy in patients with psoriasis: a summary of safety, based on an integrated multistudy database

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2809%2971257-8

Impact of body mass index and obesity on clinical response to systemic treatment for psoriasis. Evidence from the Psocare project.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2809%2971257-8

Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2809%2971257-8

Effect of anti-tumor necrosis factor-alpha therapies on body mass index in patients with psoriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2809%2971257-8

Diverse effects of infliximab and etanercept on T lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2809%2971257-8

Programmed cell death of keratinocytes in infliximab-treated plaque-type psoriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2809%2971257-8

Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2809%2971257-8

Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2809%2971257-8

Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2809%2971257-8

Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2809%2971257-8

A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2809%2971257-8

Recommendations for the long-term treatment of psoriasis with infliximab: a dermatology expert group consensus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2809%2971257-8

Clinical pharmacokinetics and use of infliximab

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2809%2971257-8

Re-induction as a possible alternative modality of dose escalation of infliximab: a prospective evaluation in a small series of psoriatic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2809%2971257-8

Review article: Infliximab therapy for inflammatory bowel disease--seven years on

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2809%2971257-8

Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2809%2971257-8

Review and expert opinion on prevention and treatment of infliximab-related infusion reactions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2809%2971257-8

[Reactions to infliximab infusions in dermatologic patients: consensus statement and treatment protocol. Working Group of the Grupo Español de Psoriasis de la Academia Española de Dermatología y Venereología ].

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2809%2971257-8

Tumor necrosis factor and its blockade in granulomatous infections: differential modes of action of infliximab and etanercept?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2809%2971257-8

Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2809%2971257-8

Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2809%2971257-8

Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2809%2971257-8

Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2809%2971257-8

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2809%2971257-8

Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2809%2971257-8

Clinical pharmacokinetics of TNF antagonists: how do they differ?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2809%2971257-8

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2809%2971257-8

Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2809%2971257-8

Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2809%2971257-8

From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2809%2971257-8

10.1016/S0001-7310(09)71257-8

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19558918%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

1 reference